Differential Effects in Cardiovascular Markers between High-Dose Angiotensin II Receptor Blocker Monotherapy and Combination Therapy of ARB with Calcium Channel Blocker in Hypertension (DEAR Trial)

Table 2

Changes in blood pressure during the study period.

Therapy	Olmesartan		Olmesartan + Azelnidipine		P
	Baseline	12 months	Baseline	12 months	Between therapies
Clinic SBP	157 ± 2	141 ± 3*	165 ± 6	143±4^∗	.430
Clinic DBP	100 ± 2	87 ± 3*	106 ± 4	91±3^∗	.813
24-h SBP	144 ± 3	129 ± 3*	147 ± 4	134±4^∗	.726
24-h DBP	90 ± 2	81 ± 2*	92 ± 2	82±2^∗	.779
Daytime SBP	149 ± 4	133 ± 3*	152 ± 4	138±4^∗	.708
Daytime DBP	93 ± 9	84 ± 2*	94 ± 3	85±2^∗	.820
Nighttime SBP	128 ± 5	113 ± 3*	129 ± 4	116±5^∗	.852
Nighttime DBP	81 ± 4	72 ± 2	83 ± 2	72±2^∗	.684
Nocturnal decrease	17 ± 2	9 ± 2*	20 ± 3	15±3	.472
Morning surge	33 ± 5	32 ± 3	40 ± 5	38±4	.921
SBP variability	21 ± 2	21 ± 2	23 ± 1	22±2	.738

Units are mmHg. Data are the means ± SEM. SBP, systolic blood pressure; DBP, diastolic blood pressure. *𝑃<.05 versus the baseline value.